High Dose PPI denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for high dose ppi are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies High-Dose PPI as Experimental

An experimental or investigational denial for high-dose PPI therapy is unusual, because proton pump inhibitors as a drug class are well-established and widely used. However, Cigna may apply this denial when the specific dose level or dosing frequency prescribed exceeds what Cigna's clinical policy defines as standard, or when the indication for which high-dose therapy is prescribed is one Cigna has categorized as lacking sufficient evidence for that intensity of treatment. It can also occur if the drug is being used in a pediatric population, an off-label indication, or a dosing interval not reflected in the FDA-approved labeling.

## Why This Denial Is Appealable

High-dose PPI use is supported by clinical practice guidelines from major gastroenterology societies — including the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) — for defined indications. If the prescribing clinician can cite the applicable guideline organization's recommendation for this patient's specific diagnosis, and document that the patient's clinical situation falls within that recommended use, the "experimental" characterization is directly challengeable. The appeal should establish that this is a guideline-concordant, evidence-based use of an approved drug class.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plans) or applicable state law within the timeframe on the denial notice. Explicitly challenge the factual basis of the experimental classification.
• External review: After exhausting internal remedies, ACA §2719 entitles you to independent external review by an IRO. The standard window is approximately four months from the final internal denial. Expedited review is available for urgent clinical situations.

## Concrete Appeal Steps and Timeline

1. Obtain Cigna's Clinical Policy Bulletin for PPI therapy and identify the specific basis for the experimental classification (dose level, indication, patient population). 2. Have the prescribing gastroenterologist or primary care physician document the diagnosis and the clinical practice guideline basis for the high-dose prescription. 3. Confirm that the dosing is within the FDA-approved labeling for the specific drug, or document the clinical rationale if it is off-label. 4. Submit a Level 1 internal appeal with the clinical rationale, guideline reference, and supporting chart documentation. 5. Escalate to external IRO review if denied internally.

## Documentation to Gather

• Diagnosis confirmation: Endoscopy reports, pathology (e.g., Barrett's biopsy), ambulatory pH study, or other objective evidence establishing the diagnosis that requires high-dose therapy.
• FDA labeling: The prescribing information for the specific PPI confirming that high-dose use is reflected in the approved label (or, if off-label, documenting the clinical basis).
• Guideline reference: A statement from the prescribing clinician citing the relevant ACG or AGA guideline organization's recommendation for high-dose therapy in this indication — referenced by organization and guideline title, without quoting specific numeric thresholds.
• Treatment history: Prior treatment records showing the course of standard-dose therapy and its documented inadequacy.
• Prescriber letter of medical necessity: A specific letter from the treating gastroenterologist or internist explaining the clinical necessity of high-dose therapy for this patient.

## Criteria-Mapping Structure

Obtain Cigna's Clinical Policy Bulletin and reproduce each criterion for what constitutes non-experimental PPI use. Map each criterion to a specific chart fact, FDA labeling reference, or guideline organization citation. Highlight any place where Cigna's criteria contradict the relevant professional society's published guideline — that gap is the core of your appeal argument.